HEMATOLOGICAL ADVERSE EVENTS ON THE BACKGROUND OF ANTIVIRAL THERAPY IN PATIENTS WITH CHRONIC HEPATITIS C

Abstract

Currently, the main etiotropic method of treating chronic hepatitis C is combination therapy with standard interferon-a (IFN-a) or pegylated interferon-a (PIFN-a) in combination with ribavirin. Despite significant advances in AVT in CHC patients, adverse events may occur during treatment, which force either to reduce the dosage of drugs or stop treatment altogether.